Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/34117
DC FieldValueLanguage
dc.contributor.authorChiang, M.C.en_US
dc.contributor.author李茂榮zh_TW
dc.contributor.authorChen, C.M.en_US
dc.contributor.authorLee, M.R.en_US
dc.contributor.authorChen, H.W.en_US
dc.contributor.authorChen, H.M.en_US
dc.contributor.authorWu, Y.S.en_US
dc.contributor.authorHung, C.H.en_US
dc.contributor.authorKang, J.J.en_US
dc.contributor.authorChang, C.P.en_US
dc.contributor.authorChang, C.en_US
dc.contributor.authorWu, Y.R.en_US
dc.contributor.authorTsai, Y.S.en_US
dc.contributor.authorChern, Y.en_US
dc.date2010zh_TW
dc.date.accessioned2014-06-06T07:47:12Z-
dc.date.available2014-06-06T07:47:12Z-
dc.identifier.issn0964-6906zh_TW
dc.identifier.urihttp://hdl.handle.net/11455/34117-
dc.description.abstractHuntington's disease (HD) is a neurodegenerative disease caused by the expansion of a CAG trinucleotide repeat in exon 1 of the huntingtin (HTT) gene. Here, we report that the transcript of the peroxisome proliferator-activated receptor-gamma (PPAR gamma), a transcription factor that is critical for energy homeostasis, was markedly downregulated in multiple tissues of a mouse model (R6/2) of HD and in lymphocytes of HD patients. Therefore, downregulation of PPAR gamma seems to be a pathomechanism of HD. Chronic treatment of R6/2 mice with an agonist of PPAR gamma (thiazolidinedione, TZD) rescued progressive weight loss, motor deterioration, formation of mutant Htt aggregates, jeopardized global ubiquitination profiles, reduced expression of two neuroprotective proteins (brain-derived neurotrophic factor and Bcl-2) and shortened life span exhibited by these mice. By reducing HTT aggregates and, thus, ameliorating the recruitment of PPAR gamma into HTT aggregates, chronic TZD treatment also elevated the availability of the PPAR gamma protein and subsequently normalized the expression of two of its downstream genes (the glucose transporter type 4 and PPAR gamma coactivator-1 alpha genes). The protective effects described above appear to have been exerted, at least partially, via direct activation of PPAR gamma in the brain, as TZD was detected in the brains of mice treated with TZD and because a PPAR gamma agonist (rosiglitazone) protected striatal cells from mHTT-evoked energy deficiency and toxicity. We demonstrated that the systematic downregulation of PPAR gamma seems to play a critical role in the dysregulation of energy homeostasis observed in HD, and that PPAR gamma is a potential therapeutic target for this disease.en_US
dc.language.isoen_USzh_TW
dc.relationHuman Molecular Geneticsen_US
dc.relation.ispartofseriesHuman Molecular Genetics, Volume 19, Issue 20, Page(s) 4043-4058.en_US
dc.relation.urihttp://dx.doi.org/10.1093/hmg/ddq322en_US
dc.subjectubiquitin-proteasome systemen_US
dc.subjecttransgenic mouse modelen_US
dc.subjectcentral-nervous-systemen_US
dc.subjecturea cycle deficiencyen_US
dc.subjectexpanded cag repeaten_US
dc.subjectppar-gammaen_US
dc.subjectmutant huntingtinen_US
dc.subjectinsulin-resistanceen_US
dc.subjectadipose-tissueen_US
dc.subjectneurodegenerative diseasesen_US
dc.titleModulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gammaen_US
dc.typeJournal Articlezh_TW
dc.identifier.doi10.1093/hmg/ddq322zh_TW
Appears in Collections:化學系所
文件中的檔案:

取得全文請前往華藝線上圖書館



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.